AbbVie Inc. (VIE:ABBV)

Austria flag Austria · Delayed Price · Currency is EUR
178.20
+0.40 (0.22%)
Last updated: Sep 1, 2025, 1:00 PM CET
0.22%
Market Cap317.75B
Revenue (ttm)49.67B
Net Income (ttm)3.17B
Shares Outn/a
EPS (ttm)1.79
PE Ratio100.23
Forward PE16.00
Dividend5.86 (3.30%)
Ex-Dividend DateJul 15, 2025
Volumen/a
Average Volumen/a
Open178.00
Previous Close177.80
Day's Range178.00 - 178.20
52-Week Range149.00 - 204.15
Betan/a
RSI59.22
Earnings DateOct 29, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Vienna Stock Exchange
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.